A 42-year-old woman with bipolar disorder has been on risperidone 4 mg/day for 2 years with good symptom control. She presents with amenorrhea for 4 months, galactorrhea, and decreased libido. Serum prolactin is 85 ng/mL (normal <25 ng/mL). Pregnancy test is negative. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** The patient has **antipsychotic-induced hyperprolactinemia** secondary to risperidone (a potent D~2~ dopamine antagonist). Elevated prolactin causes amenorrhea, galactorrhea, and sexual dysfunction. ## Mechanism of Risperidone-Induced Hyperprolactinemia **High-Yield:** Risperidone blocks dopamine D~2~ receptors in the tuberoinfundibular pathway. Dopamine normally inhibits prolactin release; its blockade leads to unopposed prolactin secretion. | Antipsychotic | Prolactin Risk | Mechanism | |---|---|---| | **Risperidone** | **Very High** | Potent D~2~ antagonism; poor BBB penetration of prolactin-lowering agents | | **Paliperidone** | **Very High** | Active metabolite of risperidone | | **Amisulpride** | **High** | Selective D~2~/D~3~ antagonism | | **Aripiprazole** | **Very Low** | Partial D~2~ agonist; increases dopamine | | **Quetiapine** | **Low** | Weak D~2~ antagonism; rapid dissociation | | **Clozapine** | **Low** | Minimal D~2~ antagonism | ## Management Algorithm ```mermaid flowchart TD A[Antipsychotic-induced hyperprolactinemia confirmed]:::outcome B{Symptomatic?}:::decision B -->|Yes| C{Switch to low-prolactin SGA?}:::decision B -->|No| D[Monitor; no intervention] C -->|Yes| E[Switch to aripiprazole, quetiapine, or clozapine]:::action C -->|No| F[Add dopamine agonist if switch not feasible] E --> G[Taper original agent over 2-4 weeks]:::action G --> H[Recheck prolactin in 4-6 weeks]:::action H --> I{Prolactin normalized?}:::decision I -->|Yes| J[Continue new SGA]:::outcome I -->|No| K[Reassess adherence; consider dopamine agonist] ``` **Clinical Pearl:** Dopamine agonists (bromocriptine, cabergoline) are **second-line** for antipsychotic-induced hyperprolactinemia because: - They may worsen psychotic symptoms (dopamine agonism). - They are less effective when the D~2~ receptor remains blocked by the antipsychotic. - **Switching to a low-prolactin antipsychotic is preferred** if the patient is stable on the current agent. ## Why Switch Rather Than Add Bromocriptine? **Mnemonic: SWITCH > DOPAMINE AGONIST** = **S**witch removes the cause, **W**hile dopamine agonists fight D~2~ blockade (less effective), **I**ncreases psychosis risk, **T**wo-drug regimen (complexity), **C**ost-ineffective, **H**igher relapse risk. 1. **Aripiprazole** (partial D~2~ agonist) — actively increases dopamine; prolactin typically normalizes. 2. **Quetiapine** — weak D~2~ antagonism; prolactin often improves. 3. Both have good efficacy in bipolar disorder and allow gradual tapering of risperidone. ## Why Not the Other Options? - **Bromocriptine + continue risperidone:** Dopamine agonists are second-line; they may precipitate psychotic relapse and are less effective when D~2~ remains blocked. Switching is superior. - **Dose reduction alone:** Lowering risperidone to 2 mg may compromise psychiatric stability; switching to a low-prolactin agent is safer. - **MRI brain first:** While prolactinoma must be excluded in severe hyperprolactinemia (>200 ng/mL) or with headache/visual symptoms, this patient's prolactin (85 ng/mL) and clinical picture are classic for drug-induced hyperprolactinemia. MRI is not the first step; switch antipsychotic first, then recheck prolactin. If prolactin remains >100 ng/mL despite switching, MRI is warranted. [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 397]